Who Owns Xeris Company?

Xeris Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Xeris Pharmaceuticals?

Unraveling the ownership structure of Xeris Pharmaceuticals is key to understanding its future. From its inception to its current standing, Xeris's ownership has undergone significant transformations, especially after pivotal events like the Strongbridge Biopharma acquisition in October 2021. This journey reveals the forces shaping Xeris's strategic direction and market performance.

Understanding the Xeris SWOT Analysis is essential, as it helps to understand the company's position in the market. Knowing the Xeris ownership and its major shareholders provides insights into the company's governance and strategic decisions. This analysis explores who founded Xeris company, the influence of Xeris investors, and the roles of Xeris executives, offering a comprehensive view of this dynamic biopharmaceutical firm and its Xeris stock.

The specifics of the original equity split among the founders of the Xeris company, Xeris Pharmaceuticals, Inc., in 2005 are not available in public records. The initial ownership structure would have been determined by the early private funding rounds, which likely involved angel investors, venture capital, and potentially friends and family. These early agreements would have included standard provisions like vesting schedules for founders' equity and potential buy-sell clauses to manage ownership transitions.

Understanding the early ownership of Xeris Pharmaceuticals is key to grasping its evolution. The company's journey from its inception to its current status involves multiple stages of investment and strategic decisions that have shaped its ownership structure. Information about the founders and initial investors is crucial for a comprehensive view of Xeris's history and development. This includes details on how the Xeris stock was distributed among the founders and early investors.

The early ownership structure of Xeris Pharmaceuticals was significantly impacted by a major acquisition. This shift in ownership is a critical aspect of the company's history. To fully understand the current ownership landscape, it's essential to examine the impact of the acquisition on the original ownership structure.

Founding and Initial Funding

The Xeris company was founded in 2005. Early funding rounds likely included angel investors and venture capital. These initial investments helped establish the company and its early operations.

Ownership Agreements

Early agreements included vesting schedules for founders' equity. Buy-sell clauses were likely in place to manage ownership transitions. These agreements are standard in early-stage companies.

Private Funding Rounds

Xeris Pharmaceuticals likely went through multiple private funding rounds. These rounds would have diluted the founders' initial ownership. Each round brought in new investors.

Early Investors

Early investors may have included friends and family. Venture capital firms played a key role in providing capital. These investors helped drive the company's early growth.

Equity Distribution

The initial equity distribution among founders is not publicly available. The distribution would have been based on contributions and agreements. Understanding this is key to Xeris ownership.

Ownership Changes

Ownership has changed over time due to funding and acquisitions. Major shifts occurred with the acquisition of other companies. These changes are important to note.

Acquisition Impact

A significant change in Xeris ownership occurred with the acquisition of Strongbridge Biopharma plc, which closed in October 2021. This strategic move reshaped the company's shareholder base. Former Xeris shareholders were expected to own approximately 60% of the combined company, while former Strongbridge shareholders were expected to own approximately 40%. This consolidation fundamentally altered the founding ownership structure. For more information on the company's financial performance and business model, you can read Revenue Streams & Business Model of Xeris.

• The acquisition of Strongbridge Biopharma plc was completed in October 2021.
• Former Xeris shareholders held approximately 60% of the combined company.
• Former Strongbridge shareholders held approximately 40% of the combined company.
• This transaction marked a significant shift in Xeris ownership.

Xeris SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Xeris Biopharma Holdings, Inc. (XERS), a publicly traded entity on Nasdaq, is primarily influenced by institutional investors and company insiders. As of April 2025, institutional investors collectively held a significant portion of the company's shares, reflecting a strong vote of confidence from the investment community. This ownership structure, alongside insider holdings, plays a crucial role in shaping the company's strategic direction and financial performance. The company's history, including its evolution and key events, has shaped its current ownership dynamics.

The company's stock performance and investor confidence are closely tied to its ownership structure. The share price increased substantially between April 17, 2024, and April 16, 2025, indicating growing investor confidence. This performance is influenced by the major shareholders and their strategic decisions. A deeper understanding of the company's ownership is crucial for investors and stakeholders alike. For further insights, consider exploring the Competitors Landscape of Xeris.

Key institutional investors as of December 31, 2024, included BlackRock, Inc. with 10,821,128 shares, Vanguard Group Inc. holding 7,899,063 shares, and Geode Capital Management, LLC with 3,351,426 shares. State Street Corp. held 3,341,874 shares, while Rosalind Advisors, Inc. held 3,104,995 shares. Morgan Stanley increased its holdings significantly, and other major stakeholders included Aigh Capital Management LLC, Renaissance Technologies LLC, Caxton Corp., and Millennium Management LLC. The detailed breakdown of these holdings provides a clear picture of the major shareholders influencing the company's trajectory.

Ownership Insights for Xeris Pharmaceuticals

Understanding Xeris ownership structure is vital for investors and stakeholders. Institutional investors and company insiders significantly influence the company's direction and performance.

• Institutional investors hold a substantial stake in Xeris stock.
• Insider ownership reflects the commitment of company leadership.
• The share price has shown positive growth, reflecting investor confidence.
• Major shareholders include BlackRock, Vanguard, and State Street Corp.

Xeris PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Xeris Biopharma Holdings, Inc. plays a vital role in governing the company. As of March 28, 2025, the board welcomed James Brady as a new director. This appointment followed the resignation of Ricki Fairley and John Schmid's decision not to seek re-election at the 2025 Annual Stockholders Meeting. These changes will reduce the board to eight members. James Brady brings financial expertise from his previous roles at AstraZeneca, including his time as Chief Financial Officer of MedImmune. Marla Persky serves as the Chairperson of the Board.

Key insider board members and officers, along with their approximate shareholdings as of May 2025, include John P. Shannon (CEO) with 9.85%, Kevin McCulloch with 6.17%, Steven M. Pieper with 5.2%, Beth P. Hecht with 4.96%, John H. Johnson with 3.27%, Dr. Anh Nguyen, M.D., with 1.1%, Dr. Jeffrey W. Sherman, F.A.C.P., M.D., with 0.6%, and Dr. Garheng Kong, M.D., PhD, also with 0.6%. These details are crucial for understanding the Xeris ownership structure and the influence of key Xeris executives.

As of April 14, 2025, Xeris had 156,384,578 shares of common stock outstanding. Each stockholder of record is entitled to one vote per share. The company conducts virtual annual meetings to enhance accessibility and shareholder participation. The 2025 Annual Meeting of Stockholders was held on June 4, 2025. Shareholders voted on matters such as the election of Class I directors and the ratification of the independent registered public accounting firm. For more insights into the company's strategic direction, consider reading about the Growth Strategy of Xeris.

Understanding Xeris Ownership

The ownership structure of Xeris Pharmaceuticals is primarily influenced by its board of directors and major shareholders. Key executives hold significant shares, impacting the company's direction. The voting power is distributed among the shareholders based on the number of shares they own.

• The CEO, John P. Shannon, holds a significant percentage of the shares.
• Other executives and board members also have considerable ownership stakes.
• Shareholders vote on critical decisions, including director elections.
• The company's financial reports provide detailed information about the Xeris stock and ownership.

Xeris Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In the past few years, Xeris Biopharma Holdings has seen significant changes in its ownership structure. A key event was the acquisition of Strongbridge Biopharma plc in October 2021. This merger resulted in former Xeris shareholders owning about 60% of the combined entity, while former Strongbridge shareholders held approximately 40%. This strategic move broadened the company's product offerings and market presence.

Institutional ownership of Xeris Biopharma Holdings has grown. As of June 13, 2025, 332 institutional owners held 98,903,220 shares, representing 61.75% of the shares (excluding 13D/G filings). This marks a 31.42% increase in institutional shares (long) quarter-over-quarter. Total institutional ownership stood at 48.73% as of April 2025. Major investors like BlackRock, Inc., and Vanguard Group Inc. have either increased or maintained substantial holdings as of December 31, 2024. This increased institutional interest often indicates confidence in the company.

Insider ownership remains relatively stable. Insiders held 35.05% of shares in May 2025. While there have been insider sales, such as Beth Hecht's sale of 40,000 shares in March 2025, other insiders have also purchased shares. The company's strong financial performance, including record total revenue of $203 million in 2024 and projected revenue of $260-275 million for 2025, further contributes to its attractiveness to investors. The company also anticipates ending 2024 with over $71 million in cash, cash equivalents, and short-term investments, achieving positive cash flow in Q4.

Xeris Ownership Overview

The ownership of Xeris Pharmaceuticals has seen shifts, with increased institutional interest and stable insider holdings. These trends reflect the company's growth and financial success. Increased institutional ownership often signals confidence in the future of the company.

Impact of Acquisitions

The Strongbridge Biopharma acquisition significantly altered the Xeris ownership structure. This merger expanded the company's product portfolio. This strategic move broadened the company's market presence.

Financial Performance and Investor Sentiment

Xeris's strong financial results, including record revenue and positive cash flow, have boosted investor confidence. The company's stock price has seen a significant increase. These factors contribute to its appeal to Xeris investors.

Insider Activity and Future Outlook

While some insiders have sold shares, others have bought, indicating varied perspectives. The company's projected revenue growth for 2025 suggests a positive outlook. The company is focused on future growth.

Xeris Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs